DAS 181

Drug Profile

DAS 181

Alternative Names: DAS 181-F02; DAS181; DAS181-F04; Fludase; NEX DAS181; ParaDase

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma; NexBio
  • Class Antivirals; Recombinant fusion proteins
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parainfluenza virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections; Parainfluenza virus infections
  • Preclinical Enterovirus infections; Polyomavirus infections
  • Research Metapneumovirus infections; Respiratory syncytial virus infections
  • No development reported Asthma

Most Recent Events

  • 10 Oct 2017 DAS 181 receives Breakthrough Therapy status for Parainfluenza virus infections in USA
  • 10 Oct 2017 DAS 181 is available under expanded access programme for the treatment of Parainfluenza virus infections in USA
  • 10 Oct 2017 Ansun BioPharma plans a phase III trial in Parainfluenza virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top